enanta pharmaceuticals inc - ENTA

ENTA

Close Chg Chg %
13.77 0.18 1.31%

Pre-Market

13.95

+0.18 (1.31%)

Volume: 108.33K

Last Updated:

Apr 9, 2026, 4:00 PM EDT

Company Overview: enanta pharmaceuticals inc - ENTA

ENTA Key Data

Open

$13.67

Day Range

13.62 - 14.12

52 Week Range

4.12 - 17.15

Market Cap

$399.60M

Shares Outstanding

29.02M

Public Float

27.53M

Beta

1.00

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$3.20

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

142.33K

 

ENTA Performance

1 Week
 
6.16%
 
1 Month
 
9.84%
 
3 Months
 
6.41%
 
1 Year
 
197.44%
 
5 Years
 
-71.38%
 

ENTA Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 7
Full Ratings ➔

About enanta pharmaceuticals inc - ENTA

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

ENTA At a Glance

Enanta Pharmaceuticals, Inc.
4 Kingsbury Avenue
Watertown, Massachusetts 02472
Phone 1-617-607-0800 Revenue 65.32M
Industry Pharmaceuticals: Major Net Income -81,889,000.00
Sector Health Technology Employees 120
Fiscal Year-end 09 / 2026
View SEC Filings

ENTA Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 3.91
Price to Book Ratio 3.956
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -3.313
Enterprise Value to Sales 4.096
Total Debt to Enterprise Value 0.751

ENTA Efficiency

Revenue/Employee 544,366.667
Income Per Employee -682,408.333
Receivables Turnover 9.492
Total Asset Turnover 0.191

ENTA Liquidity

Current Ratio 4.208
Quick Ratio 4.208
Cash Ratio 3.89

ENTA Profitability

Gross Margin 92.98
Operating Margin -130.655
Pretax Margin -127.899
Net Margin -125.358
Return on Assets -23.961
Return on Equity -84.626
Return on Total Capital -30.812
Return on Invested Capital -29.734

ENTA Capital Structure

Total Debt to Total Equity 310.67
Total Debt to Total Capital 75.65
Total Debt to Total Assets 68.686
Long-Term Debt to Equity 258.356
Long-Term Debt to Total Capital 62.911
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Enanta Pharmaceuticals Inc - ENTA

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
86.16M 79.20M 67.64M 65.32M
Sales Growth
-11.24% -8.07% -14.61% -3.42%
Cost of Goods Sold (COGS) incl D&A
2.97M 2.37M 2.34M 4.59M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
2.97M 2.37M 2.34M 4.59M
Depreciation
2.97M 2.37M 2.34M 4.59M
Amortization of Intangibles
- - - -
-
COGS Growth
- -20.25% -1.48% +96.32%
Gross Income
83.19M 76.83M 65.30M 60.74M
Gross Income Growth
- -7.64% -15.01% -6.98%
Gross Profit Margin
+96.55% +97.01% +96.55% +92.98%
2022 2023 2024 2025 5-year trend
SG&A Expense
207.03M 214.04M 186.99M 146.09M
Research & Development
164.52M 163.52M 131.48M 106.74M
Other SG&A
42.51M 50.52M 55.51M 39.35M
SGA Growth
+1.83% +3.39% -12.64% -21.87%
Other Operating Expense
- - - -
-
Unusual Expense
- (83.00K) (73.00K) (39.00K)
EBIT after Unusual Expense
(123.76M) (137.21M) (121.62M) (85.31M)
Non Operating Income/Expense
1.57M 11.36M 14.77M 9.44M
Non-Operating Interest Income
1.57M 11.36M 14.77M 9.44M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- 5.15M 10.94M 7.68M
Interest Expense Growth
- - +112.51% -29.79%
-
Gross Interest Expense
- 5.15M 10.94M 7.68M
Interest Capitalized
- - - -
-
Pretax Income
(122.19M) (131.00M) (117.79M) (83.55M)
Pretax Income Growth
-13.58% -7.21% +10.08% +29.07%
Pretax Margin
-141.82% -165.39% -174.15% -127.90%
Income Tax
(433.00K) 2.82M (1.74M) (1.66M)
Income Tax - Current - Domestic
(449.00K) 2.82M (1.74M) (1.66M)
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - 16.00K
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(121.75M) (133.82M) (116.05M) (81.89M)
Minority Interest Expense
- - - -
-
Net Income
(121.75M) (133.82M) (116.05M) (81.89M)
Net Income Growth
-54.13% -9.91% +13.28% +29.43%
Net Margin Growth
-141.31% -168.95% -171.58% -125.36%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(121.75M) (133.82M) (116.05M) (81.89M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(121.75M) (133.82M) (116.05M) (81.89M)
EPS (Basic)
-5.9096 -6.3816 -5.485 -3.8381
EPS (Basic) Growth
-50.90% -7.99% +14.05% +30.03%
Basic Shares Outstanding
20.60M 20.97M 21.16M 21.34M
EPS (Diluted)
-5.9096 -6.3816 -5.485 -3.8381
EPS (Diluted) Growth
-50.90% -7.99% +14.05% +30.03%
Diluted Shares Outstanding
20.60M 20.97M 21.16M 21.34M
EBITDA
(120.87M) (134.84M) (119.36M) (80.76M)
EBITDA Growth
-13.77% -11.55% +11.48% +32.33%
EBITDA Margin
-140.29% -170.24% -176.47% -123.63%

Snapshot

Average Recommendation BUY Average Target Price 18.50
Number of Ratings 7 Current Quarters Estimate -0.493
FY Report Date 06 / 2026 Current Year's Estimate -2.47
Last Quarter’s Earnings -0.53 Median PE on CY Estimate N/A
Year Ago Earnings -3.84 Next Fiscal Year Estimate -1.991
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 4 4 5 4
Mean Estimate -0.49 -0.68 -2.47 -1.99
High Estimates -0.25 -0.33 -1.31 -1.60
Low Estimate -0.67 -0.99 -3.85 -2.53
Coefficient of Variance -35.52 -39.90 -36.95 -19.93

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 5 5 3
OVERWEIGHT 1 1 1
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Overweight

Enanta Pharmaceuticals Inc in the News